Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 0.63 |
| ▸ | CDK2 | P24941 | 7/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13119183 | 0.91 | GSK3B (0.65) | GSK3BCDK2CCNE1 | |
| SCHEMBL12952884 | 0.88 | GSK3B (0.73) | GSK3BCDK2CCNE1 | |
| SCHEMBL13121526 | 0.86 | GSK3B (0.65) | GSK3BCDK2CCNE1 | |
| SCHEMBL13121521 | 0.86 | GSK3B (0.65) | GSK3BCDK2CCNE1 | |
| SCHEMBL13121543 | 0.84 | GSK3B (0.64) | GSK3BCDK2CCNE1 | |
| SCHEMBL12952880 | 0.84 | GSK3B (0.73) | GSK3BCDK2CCNE1 | |
| SCHEMBL12952868 | 0.84 | GSK3B (0.73) | GSK3BCDK2CCNE1 | |
| SCHEMBL13119103 | 0.84 | GSK3B (0.70) | GSK3BCDK2CCNE1 | |
| SCHEMBL13288630 | 0.84 | GSK3B (0.55) | GSK3BCDK2CCNE1 | |
| SCHEMBL12954388 | 0.84 | GSK3B (0.75) | GSK3BCDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | GSK3B 695/4885CDK2 1/4885CCNE1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.